179 related articles for article (PubMed ID: 37909930)
1. [New Insulins for Type 1 Diabetes treatment].
Rumié Carmi HK; Domínguez-Menéndez G; Araya M; Martínez-Aguayo A
Andes Pediatr; 2023 Jun; 94(3):278-285. PubMed ID: 37909930
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars and Novel Insulins.
Ampudia-Blasco FJ
Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
[TBL] [Abstract][Full Text] [Related]
3. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
4. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
5. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
Martin ; Zhou Y; Takagi T; Tian YS
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar vs originator insulins: Systematic review and meta-analysis.
Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
[TBL] [Abstract][Full Text] [Related]
8. [Insulin therapy-new insulin analogues].
Ehren M; Klein HH
Internist (Berl); 2019 Sep; 60(9):887-894. PubMed ID: 31396651
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis.
Holmes RS; Crabtree E; McDonagh MS
Diabetes Obes Metab; 2019 Apr; 21(4):984-992. PubMed ID: 30552792
[TBL] [Abstract][Full Text] [Related]
10. The past, present, and future of basal insulins.
Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
12. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
14. Concentrated insulins: the new basal insulins.
Lamos EM; Younk LM; Davis SN
Ther Clin Risk Manag; 2016; 12():389-400. PubMed ID: 27022271
[TBL] [Abstract][Full Text] [Related]
15. Biosynthetic Human Insulin and Insulin Analogs.
Rodbard HW; Rodbard D
Am J Ther; 2020; 27(1):e42-e51. PubMed ID: 31876563
[TBL] [Abstract][Full Text] [Related]
16. New Insulins and New Aspects in Insulin Delivery.
Woo VC
Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
[TBL] [Abstract][Full Text] [Related]
17. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
[TBL] [Abstract][Full Text] [Related]
19. Advances in newer basal and bolus insulins: impact on type 1 diabetes.
Vliebergh J; Lefever E; Mathieu C
Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):1-7. PubMed ID: 33315628
[TBL] [Abstract][Full Text] [Related]
20. Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.
Stailey M; Conway SE
Consult Pharm; 2017 Jan; 32(1):42-46. PubMed ID: 28077204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
